Ann: Phase III Clinical Trial Update and New IIH Market Analysis, page-112

You are spot on and I think it is worth pointing out that we would only need to have 920 people on drug to have an annual revenue equal to the current market cap. A 1,000 people on drug would make IXC a decently profitable business. Even in the worst case, I am certain a patient population of between 2,500 and 7,500 could be achieved by IXC directly and with very limited infrastructure.

There is a profitable future for Presendin in IIH, what may have changed today is the prospect of a large sale, after a positive IIH readout. I now think we might see IIH become a commercial company. I foresee a very narrow shoestring commercialisation and the profits of which are used to advance TBI and other indications.